Table 3 Patient demographic, clinical and treatment characteristics, National Cancer Data Base 2010–2017 Surgery alone vs Surgery followed by Chemotherapy, Patients ≥70 with cTt1-3/cN0-3, Triple Negative or HER2 Positive invasive breast cancer treated with surgery and/or chemotherapy (N = 2544)
Value or no. of patients (Column %) | |||
|---|---|---|---|
Surgery only (n = 1627) | Surgery followed by chemotherapy (n = 917) | p-Value | |
Age (median, range), years | 81 (71–90) | 75 (71–90) | 0.002 |
Clinical T Stage (cT) | 0.09 | ||
T1 | 625 (38.41%) | 379 (41.33%) | |
T2 | 870 (53.47%) | 483 (52.67%) | |
T3 | 132 (8.11%) | 55 (6%) | |
Clinical N Stage (cN) | <0.001 | ||
N0 | 1354 (83.22%) | 669 (72.96%) | |
N1 | 231 (14.2%) | 204 (22.25%) | |
N2 | 25 (1.54%) | 32 (3.49%) | |
N3 | 17 (1.04%) | 12 (1.31%) | |
Year of diagnosis | 0.35 | ||
2010 | 136 (8.36%) | 84 (9.16%) | |
2011 | 160 (9.83%) | 77 (8.4%) | |
2012 | 154 (9.47%) | 86 (9.38%) | |
2013 | 182 (11.19%) | 102 (11.12%) | |
2014 | 198 (12.17%) | 112 (12.21%) | |
2015 | 197 (12.11%) | 105 (11.45%) | |
2016 | 307 (18.87%) | 152 (16.58%) | |
2017 | 293 (18.01%) | 199 (21.7%) | |
HER2 | <0.001 | ||
Negative | 928 (57.04%) | 459 (50.05%) | |
Positive | 699 (42.96%) | 458 (49.95%) | |
ER | 0.63 | ||
Negative | 1125 (69.15%) | 624 (68.05%) | |
Positive | 501 (30.79%) | 293 (31.95%) | |
Unknown | 1 (0.06%) | 0 | |
PR | 0.33 | ||
Negative | 1262 (77.57%) | 700 (76.34%) | |
Positive | 365 (22.43%) | 216 (23.56%) | |
Unknown | 0 | 1 (0.11%) | |
Hormone Receptor | 0.45 | ||
Negative | 1113 (68.41%) | 614 (66.96%) | |
Positive | 514 (31.59%) | 303 (33.04%) | |
Triple Negative | <0.001 | ||
No | 699 (42.96%) | 458 (49.95%) | |
Yes | 928 (57.04%) | 459 (50.05%) | |
CCDMa | 0.007 | ||
2 | 1052 (64.66%) | 641 (69.9%) | |
3 | 575 (35.34%) | 276 (30.1%) | |
